Mirtazapine added to SSRIs for treatment resistant depression in primary care: a placebo controlled randomised controlled trial - Mirtazapine for treatment resistant depression

niversity of Bristol0 个研究点目标入组 470 人开始时间: 2013年6月7日最近更新: 2018年9月10日

适应症

试验速览

暂无简介。

•Eligible patients are those aged 18 years or over, who are currently taking any of the following SSRI or SNRI antidepressants: fluoxetine, sertraline, citalopram, escitalopram, fluvoxamine, paroxetine, duloxetine, or venlafaxine; and who have done so for at least 6 weeks at recommended (BNF) doses. Patients who score 14 or more on the Beck Depression Inventory (BDI), have adhered to their medication, and meet ICD-10 criteria for depression (assessed using the Computerised Interview Schedule – Revised version (CIS-R), will be invited to participate.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 390
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 80

•GPs will be asked to exclude patients who have bipolar disorder, psychosis, dementia, or alcohol/substance abuse/dependence or who are pregnant, planning to become pregnant or breastfeeding. In addition, we will exclude patients who: are not able to complete the study questionnaires or have a past history of an adverse reaction to mirtazapine.

发起方

niversity of Bristol